2008-07-02 20:19:19 - www.companiesandmarkets.com adds new report - Premium Company Profile - BioMarin Pharmaceutical Inc.

www.companiesandmarkets.com/Summary-Company-Profile/Premium-Comp ..
Introduction

BioMarin Pharmaceutical is a specialty biopharmaceutical company focused on the development of first-to-market treatments for rare, genetic diseases. The company commercializes two enzyme replacement therapies for lysosomal storage disorders (LSD): Aldurazyme, a treatment for mucopolysaccharidoses I (marketed through a joint venture with Genzyme), and Naglazyme, a treatment for MPS VI.



Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business

description, segment analysis, 5-year financial trends, key products and key competitors
Includes information on suppliers/ partners, shareholding structure and key employees with biographies


Highlights

BioMarin´s product portfolio comprises two approved products and multiple clinical and preclinical product candidates. Approved products include Naglazyme (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin.



BioMarin derives its revenues from product sales of Naglazyme and Orapred; royalties related to the FDA approval of the marketing application for Orapred ODT; and license and contract research revenue under its agreement with Merck Serono. The company´s total revenue increased from $19 million in 2004 to $ 84 million in 2006.



BioMarin´s major contributor to sales growth out to 2010 will be the product sales of Naglazyme, forecasted to increase at a CAGR of 60%, from $50 million in 2006 to $328 million in 2010. This represents an absolute growth of +279 million for the same period.



Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization